ATE156704T1 - Neurologische wirkstoffe zur nasalen verabreichung an das gehirn - Google Patents

Neurologische wirkstoffe zur nasalen verabreichung an das gehirn

Info

Publication number
ATE156704T1
ATE156704T1 AT91901158T AT91901158T ATE156704T1 AT E156704 T1 ATE156704 T1 AT E156704T1 AT 91901158 T AT91901158 T AT 91901158T AT 91901158 T AT91901158 T AT 91901158T AT E156704 T1 ATE156704 T1 AT E156704T1
Authority
AT
Austria
Prior art keywords
brain
nasal administration
neurological agents
agents
neurologic
Prior art date
Application number
AT91901158T
Other languages
English (en)
Inventor
William H Frey Iii
Original Assignee
Ramsey Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramsey Foundation filed Critical Ramsey Foundation
Application granted granted Critical
Publication of ATE156704T1 publication Critical patent/ATE156704T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
AT91901158T 1989-12-05 1990-12-04 Neurologische wirkstoffe zur nasalen verabreichung an das gehirn ATE156704T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44630889A 1989-12-05 1989-12-05
US56874690A 1990-08-17 1990-08-17

Publications (1)

Publication Number Publication Date
ATE156704T1 true ATE156704T1 (de) 1997-08-15

Family

ID=27034575

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91901158T ATE156704T1 (de) 1989-12-05 1990-12-04 Neurologische wirkstoffe zur nasalen verabreichung an das gehirn

Country Status (6)

Country Link
EP (1) EP0504263B1 (de)
AT (1) ATE156704T1 (de)
AU (1) AU6909091A (de)
CA (1) CA2070823C (de)
DE (1) DE69031279T2 (de)
WO (1) WO1991007947A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU682308C (en) * 1992-04-03 2006-08-17 Regents Of The University Of California, The Self-assembling polynucleotide delivery system
US5972883A (en) * 1993-03-16 1999-10-26 Yeda Research And Development Co. Ltd. Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof
DE19536246A1 (de) * 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
JPH10212241A (ja) * 1996-05-27 1998-08-11 Sumitomo Pharmaceut Co Ltd Ｂｄｎｆを安定に含有する製剤
IS4516A (is) 1997-07-01 1999-01-02 Gizurarson Sveinbjörn Nýtt lyfjaform
FR2771929B1 (fr) * 1997-12-09 2001-02-23 Biovector Therapeutics Utilisation dans une composition pharmaceutique pour l'administration par voie nasale de particules hydrophiles pour la delivrance d'agents actifs au systeme nerveux central
US7304029B1 (en) * 1998-09-03 2007-12-04 Neuren Pharmaceuticals Ltd. Neuroprotective effect of growth hormone
CA2350882C (en) 1998-11-12 2011-02-22 Life Technologies Corporation Transfection reagents
WO2000033813A1 (en) * 1998-12-09 2000-06-15 Chiron Corporation Administration of neurotrophic agents to the central nervous system
AU1261501A (en) * 1999-12-06 2001-06-18 Stanley L. Gore Compositions and methods for intranasal delivery of active agents to the brain
WO2001041782A2 (en) * 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
EP1602378A1 (de) * 1999-12-09 2005-12-07 Chiron Corporation Verfahren zur Verabreichung von Wirkstoffen in das zentrale Nervensystem oder Lymphsystem
DE10004547A1 (de) * 2000-02-02 2001-08-09 Liedtke Pharmed Gmbh Verfahren zur selektiven Verabreichung zentralnervös aktiver Stoffe
US7084126B1 (en) * 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
US20020082215A1 (en) * 2000-10-13 2002-06-27 Chiron Corporation Method for treating ischemic events affecting the central nervous system
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
EP1446102A1 (de) 2001-11-21 2004-08-18 Alexza Molecular Delivery Corporation Verabreichung von koffein durch inhalation
US20040127409A1 (en) * 2002-11-07 2004-07-01 Milkhaus Laboratory, Inc. Method of treatment of psychological conditions by administration of nerve growth factor
WO2004078943A2 (en) 2003-03-04 2004-09-16 California Institute Of Technology Alternative heterocycles for dna recognition
CA2526478A1 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
AU2004322756B2 (en) 2004-08-12 2011-04-14 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
US7618615B2 (en) 2004-08-13 2009-11-17 Healthpartners Research Foundation Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia
US9216161B2 (en) 2004-08-13 2015-12-22 Healthpartners Research Foundation Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity
US7776312B2 (en) 2004-08-13 2010-08-17 Healthpartners Research Foundation Method of treating Alzheimer's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
CU23317A1 (es) 2005-07-22 2008-10-22 Ct De Investigacia N Y Desarro Formulaciones nasales de eporh con bajo contenido de ã cido siã lico para el tratamiento de enfermedades del sistema nervioso central
JP5276982B2 (ja) 2005-08-26 2013-08-28 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ オキシトシンの投与による頭痛の処置のための方法
WO2007127163A2 (en) 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
WO2008131059A2 (en) * 2007-04-17 2008-10-30 Codman & Shurtleff, Inc. Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease
US8383865B2 (en) 2007-04-17 2013-02-26 Codman & Shurtleff, Inc. Curcumin derivatives
US9707274B2 (en) 2007-06-08 2017-07-18 Healthpartners Research & Education Methods for preventing and treating post-traumatic stress disorder (PTSD)
EA017094B1 (ru) * 2007-08-02 2012-09-28 Игорь Анатольевич Помыткин Фармацевтические композиции, содержащие холиновые соли янтарной кислоты, для интраназального введения
US7723515B1 (en) 2009-01-26 2010-05-25 Codman & Shurtleff, Inc. Methylene blue—curcumin analog for the treatment of alzheimer's disease
JP2014502953A (ja) * 2010-08-16 2014-02-06 ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク 細胞透過性治療薬の鼻腔内送達
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US8987199B2 (en) 2011-06-15 2015-03-24 Nerve Access, Inc. Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders
DE102012015248A1 (de) * 2012-08-05 2014-02-06 Naum Goldstein Verfahren zur Einbringung biologisch aktiver Substanzen ins Gehirn
US10279012B2 (en) 2013-03-11 2019-05-07 Healthpartners Research & Education Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
EP3129013A1 (de) * 2014-04-10 2017-02-15 Crowley, Patrick Verabreichung von nichtsteroidalen entzündungshemmenden wirkstoffen an das gehirn über den nasengang zur behandlung von neurologischen erkrankungen
US10195280B2 (en) 2014-07-15 2019-02-05 Life Technologies Corporation Compositions and methods for efficient delivery of molecules to cells
PL3242676T3 (pl) 2015-01-07 2024-07-15 Tonix Pharma Limited Preparaty oksytocyny zawierające magnez i sposoby ich stosowania
HRP20250215T1 (hr) 2016-04-12 2025-06-20 Tonix Pharma Limited Formulacije oksitocina koje sadrže magnezij i postupci upotrebe
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
CA3059449A1 (en) 2017-04-24 2018-11-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
SG11202000670VA (en) 2017-07-27 2020-02-27 Locus Ip Co Llc Compositions for enhancing bioavailability of pharmaceuticals, supplements and ingested substances
EP3684938A1 (de) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gentherapie zur behandlung von mukopolysaccharidose typ ii
MX2020007997A (es) 2018-02-02 2020-12-03 Alexza Pharmaceuticals Inc Dispositivo electrico de aerosol de condensacion.
TWI821343B (zh) 2018-07-27 2023-11-11 美商共結晶製藥公司 流感病毒複製之抑制劑
EP3849978B1 (de) 2018-09-10 2022-11-02 Cocrystal Pharma, Inc. Pyridopyrazin- und pyridotriazininhibitoren der influenzavirusreplikation
WO2020081751A1 (en) 2018-10-17 2020-04-23 Cocrystal Pharma, Inc. Combinations of inhibitors of influenza virus replication
EP3876932A4 (de) * 2018-11-05 2022-07-20 Rush University Medical Center Nasale verabreichung von niedrigdosiertem aspirin zur behandlung von neurodegenerativen erkrankungen und lysosomalen speicherkrankheiten
EP3887355A1 (de) 2018-11-26 2021-10-06 Cocrystal Pharma, Inc. Inhibitoren der influenzavirenreplikation
AU2020327944A1 (en) * 2019-08-10 2022-02-24 Locus Ip Company, Llc Olfactory delivery of therapeutic compounds to the central nervous system
US20230151034A1 (en) 2020-03-17 2023-05-18 Cocrystal Pharma, Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
IL297069A (en) 2020-04-10 2022-12-01 Cocrystal Pharma Inc Replication inhibitors of norovirus and corona virus
JP2024530920A (ja) 2021-08-03 2024-08-27 コクリスタル ファーマ，インコーポレイテッド コロナウイルスに対する阻害剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2260329A1 (en) * 1974-02-12 1975-09-05 Faviere Robert Aerosols contg a propellant and natural essence - free from solvents and excipients for aromatherapy
IT1212896B (it) * 1983-11-08 1989-11-30 Della Valle Francesco Metodo di somministrazione per via inalatoria di gangliosidi e derivati, e composizioni farmaceutiche relative
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US5004697A (en) * 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle

Also Published As

Publication number Publication date
EP0504263A1 (de) 1992-09-23
DE69031279T2 (de) 1998-03-19
CA2070823C (en) 1999-01-12
AU6909091A (en) 1991-06-26
EP0504263B1 (de) 1997-08-13
WO1991007947A1 (en) 1991-06-13
CA2070823A1 (en) 1991-06-06
DE69031279D1 (de) 1997-09-18

Similar Documents

Publication Publication Date Title
DE69031279D1 (de) Neurologische wirkstoffe zur nasalen verabreichung an das gehirn
KR0125921B1 (en) Method and device for the diagnosis and treatment of nasal diseases
EP0359783A4 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
BE904922A (fr) Procedes de traitement de troubles gastro-intestinaux infectieux.
ES2000428A4 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
ES2060941T3 (es) Uso de nicotina para la fabricacion de un estuche para el tratamiento de condiciones susceptibles de dicho tratamiento.
ATE264099T1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
ES2127819T3 (es) Tratamiento de la degeneracion macular.
ATE143261T1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
EP0376251A3 (en) An anticoagulant substance obtained from urine
DE68912195D1 (de) Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis.
DE3786893D1 (de) Piperidinderivat zur schmerzbehandlung.
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
DE3750983D1 (de) Biomedizinisches Verfahren und Gerät zur gesteuerten Verabreichung der Behandlung für einen Patienten in Bezug auf Wechsel im physiologischen Bedarf.
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
FR2619713B1 (fr) Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement des troubles du sommeil et de la depression
FR2561919B1 (fr) Composition pharmaceutique constituee d'une part, a titre de principe actif, par la 9a,11b-dichloro 16a-methyl 21-oxycarbonyldicyclohexyl methyloxy pregna-1,4-diene 3,20-dione et d'autre part, par un excipient pharmaceutique inerte apte a permettre l'action du produit dans le rectum ou le colon
Sunier Body and mind in old age and decay: Problems in dementia senilis, a study in literature, followed by longitudinal clinical observations.
FR2640509B1 (fr) Application de la carpipramine pour obtenir un medicament destine au traitement de l'anxiete et des troubles du sommeil
Bel'man et al. Experience with the use of cyclophosphamide in multiple sclerosis
IT1246050B (it) Impiego dell'eptastigmina nella terapia dell'ictus cerebrale.
Mathur et al. A study of progressive muscle relaxation on the treatment of dysmenorrhea.
RU93031018A (ru) Способ лечения больных с облитерирующим заболеванием нижних конечностей
Balunov et al. The experience in the use of piracetam in patients with consequences of stroke.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties